INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 120 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,786,000 | +6.9% | 146,671 | 0.0% | 0.02% | -4.2% |
| Q4 2018 | $1,671,000 | -61.2% | 146,671 | -26.2% | 0.02% | -56.4% |
| Q3 2018 | $4,312,000 | +40.5% | 198,703 | +14.4% | 0.06% | +27.9% |
| Q2 2018 | $3,069,000 | +6.1% | 173,656 | +26.4% | 0.04% | -2.3% |
| Q1 2018 | $2,892,000 | -10.2% | 137,403 | -38.2% | 0.04% | -6.4% |
| Q4 2017 | $3,222,000 | -15.7% | 222,510 | -8.1% | 0.05% | -13.0% |
| Q3 2017 | $3,821,000 | +41.2% | 242,156 | +11.1% | 0.05% | +31.7% |
| Q2 2017 | $2,707,000 | -11.3% | 217,962 | +16.0% | 0.04% | -21.2% |
| Q1 2017 | $3,052,000 | +110.6% | 187,823 | +95.6% | 0.05% | +85.7% |
| Q4 2016 | $1,449,000 | +40.8% | 96,048 | +42.3% | 0.03% | +55.6% |
| Q3 2016 | $1,029,000 | -85.7% | 67,500 | -63.6% | 0.02% | -87.0% |
| Q2 2016 | $7,201,000 | +106.4% | 185,500 | +47.8% | 0.14% | +106.0% |
| Q1 2016 | $3,489,000 | -47.7% | 125,500 | +1.2% | 0.07% | -42.7% |
| Q4 2015 | $6,670,000 | – | 124,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |